Current and future directions for treating hepatitis B virus infection

Table 3 Treatment efficacy of peginterferon treatment in hepatitis B e antigen-negative chronic hepatitis B

Ref.	No. of patients	Therapy regimen	HBV DNA suppression (%)	ALT normalization (%)	HBsAg loss (n)
cMarcellin et al[33]	177	Peg-IFNα-2a 180 μg weekly plus placebo for 48 wk	43a	59	7
	179	Peg-IFNα-2a 180 μg weekly plus LAM 100 mg daily for 48 wk	44a	60	5
	181	LAM 100 mg daily for 48 wk	29a	44	0
cPapadopoulos et al[34]	88	Peg-IFNα-2b 1.5 μg/kg weekly plus LAM 100 mg daily for 48 wk	59 (60 IU/mL below)	27	NA
	35	Peg-IFNα-2b 1.5 μg/kg weekly for 48 wk	42	40	NA
dMarcellin et al[35]	116	Peg-IFNα-2a 180 μg weekly plus placebo for 48 wk	28b	31	9 (8%)
	114	Peg-IFNα-2a 180 μg daily plus LAM 100 mg daily for 48 wk	25b	31	9 (8%)
	85	LAM 100 mg daily for 48 wk	15b	18	0 (0%)

a < 20000 copies/mL; b < 10000 copies/mL. The treatment efficacies were assessed at 24-wk follow-up^c or approximately 3-year follow-up^d. LAM: Lamivudine; Peg-IFN: Peginterferon; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; NA: Not available.